UT Dallas adds MILabs Hybrid OI/CT system to its innovative medical imaging solutions

The Department of Bioengineering at the UT Dallas is adding a MILabs Hybrid OI/CT system to its innovative medical imaging solutions. By fusing bioluminescent and fluorescent imaging with ultra-high-resolution CT, this new in-vivo imaging system enables functional treatment imaging of diseases throughout the whole-body of a small animal while providing at the same time critical tissue characterization information.

Bioengineering Department of UT Dallas

According to Prof. Kenneth Hoyt, Director of the Small Animal Imaging Core facility:

The combination of 3D optical imaging with ultra-high-resolution microCT expands applications beyond traditional optical imaging. For instance, this Hybrid OI/CT system enables to pinpoint cancer deep into tissue and at the same time, can provide distinctive microvascular characteristics such as blood supply to determine whether tumors are prone to growth and metastasis. This provides prognostic value when monitoring early tumor response to neoadjuvant treatment.”

Prof. Frederik Beekman, CEO/CSO of MILabs adds:

We are excited that Prof. Hoyt’s team, a trend-setter in the disease and treatment effects of microvascular dysfunction, has selected Hybrid 3D OI/CT for his innovative research work. We hope to further collaborate with UT Dallas on future translational research by expanding his system with nuclear imaging capabilities such as PET and SPECT”

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough imaging method enhances precision in prostate cancer treatment